Key result
This review provides a congenital cardiology perspective to fill gaps in the 2022 ESC/ERS pulmonary hypertension guidelines regarding the management of adults with congenital heart defects.
Why the study?
The 2022 ESC/ERS PH guidelines treat adults with congenital heart defects relatively superficially, leaving gaps regarding management from the perspective of congenital cardiology.
This review supplements the 2022 ESC/ERS PAH guidelines by providing detailed, specialized perspectives on managing pulmonary hypertension in adults with congenital heart disease.
Answers are grounded in this paper and cite their sources.
PH vigilance needed in ACHD; novel level-5 data leaves optimal management open for prospective trials.
The number of adults with congenital heart defects (ACHDs) is steadily increasing and is about 360,000 in Germany. Congenital heart defect (CHD) is often associated with pulmonary hypertension (PH), which sometimes develops early in untreated CHD. Despite timely treatment of CHD, PH not infrequently persists, redevelops in older age, and is associated with significant morbidity and mortality. The revised European Society of Cardiology (ESC)/European Respiratory Society (ERS) 2022 guidelines for the diagnosis and treatment of PH represent a significant contribution to the optimized care of those affected. However, the topic of "adults with congenital heart defects" is treated only relatively superficially in this context. After the first part commenting on a broad range of topics like definition, epidemiology, classification, diagnostics, genetics, risk stratification and follow-up, and gender aspects, the second part focuses on supportive therapy, special situations (pregnancy, contraception, non-cardiac surgery), targeted pharmacotherapy, organ transplantation, special management [shunt lesion, left ventricular (LV) disease, univentricular hearts], interventions, intensive care, ACHD follow-up, and future perspective. In the present article, therefore, this topic is commented on from the perspective of congenital cardiology. By examining these aspects in detail, this article aims to fill the gaps in the existing guidelines and provide a more thorough understanding from the perspective of congenital cardiology.
No takes yet. Share an insight, caveat, or question.
Kaemmerer et al. (2024) conducted a review in Pulmonary hypertension in adults with congenital heart defects (ACHDs). 2022 ESC/ERS guidelines for pulmonary hypertension was evaluated. This review provides a congenital cardiology perspective to fill gaps in the 2022 ESC/ERS pulmonary hypertension guidelines regarding the management of adults with congenital heart defects.
Synapse has enriched 10 related papers. Consider them for comparative context: